Objective:

To investigate the role of butyrate derived from gut microbiota in alleviating intestinal inflammation and its underlying mechanisms.

Approach:

Key Findings:

• Butyric acid levels were significantly lower in IBD patients compared to healthy controls (134.5 vs. 605.9, p = 0.002).
• Oral SB treatment altered intestinal microbiota composition, increasing Barnesiella abundance.
• SB treatment restored intestinal barrier function and enhanced tight junction protein expression.
• Autophagy levels increased in the SB group, indicated by higher ATG16L1 and LC3-II levels and reduced p62/SQSTM1.
• 3MA-treated mice showed significantly reduced autophagy activity and diminished protection against colonic injury.

Interpretation:

The study provides evidence that SB enhances autophagy-related signaling, which is associated with reduced inflammation in DSS-induced colitis.

Limitations:

• The study primarily focuses on a specific mouse model and may not fully represent human IBD.
• The long-term effects of SB treatment and its clinical applicability require further investigation.

Conclusion:

SB coordinates gut microbiota and enhances autophagy signaling to alleviate inflammation in DSS-induced colitis.

Attribution Notice

This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.